Arteriovenous Malformation market seen reaching $6.07 billion by 2035

Market Research Future projects the global arteriovenous malformation market will grow from $3.40 billion in 2025 to $6.07 billion by 2035, driven by rising AVM prevalence and advances in minimally invasive treatment. The forecast points to stronger demand for embolization devices, AI-assisted diagnostics and personalized neurovascular care.

Why it matters: - The forecast points to steady demand for neurovascular care as more patients are diagnosed earlier and treated with less invasive procedures. - AVMs affect roughly 1 in 100,000 people, which keeps pressure on hospitals, device makers and specialists to improve hemorrhagic stroke prevention and long-term outcomes. - The market's expected growth reflects broader adoption of embolization, neurosurgery, AI-assisted imaging and personalized treatment planning.

What happened: - Market Research Future projected the global arteriovenous malformation market will rise from $3.40 billion in 2025 to $6.07 billion by 2035. - The report put the market at $3.21 billion in 2024 and forecast a 5.96% compound annual growth rate for 2025 to 2035. - The analysis tied growth to rising AVM prevalence, minimally invasive treatment advances and personalized medicine approaches. - The report also highlighted new activity from major device makers, including a neurovascular device launch by Medtronic in August 2025, Stryker's acquisition of a neurovascular technology firm in September 2025 and Boston Scientific's partnership with a healthcare institution in July 2025. - The report included a free sample request and detailed report links: Request a free sample and Read the full report.

The details: - Endovascular embolization remained the dominant treatment segment and was projected to reach $2.8 billion by 2035. - Neurosurgery was identified as the fastest-growing treatment segment. - Brain scans were the largest diagnostic segment at $1.44 billion in 2024 and were projected to reach $2.76 billion by 2035. - Blood tests were described as the fastest-growing diagnostic segment. - True arteriovenous malformation was the largest type segment at $0.96 billion in 2024. - Cavernous malformations were projected to reach $1.25 billion by 2035. - Hospitals and clinics were the largest end-user segment and were projected to reach $2.8 billion by 2035. - Research laboratories were the fastest-growing end-user channel. - North America led with 45% of global revenue in 2025, or about $1.4 billion. - Europe held a 30% share, Asia-Pacific held about 20% and the Middle East and Africa held about 5%, or around $0.2 billion in 2025. - The report listed Medtronic, Stryker, Boston Scientific, Johnson & Johnson, Terumo Corporation, Abbott Laboratories, B. Braun Melsungen AG and Penumbra as key companies.

Between the lines: - The market story is shifting from diagnosis alone to end-to-end care, with imaging, intervention and long-term management increasingly linked. - The emphasis on AI, genetic profiling and telemedicine suggests vendors are positioning for more personalized and more distributed care pathways. - Regional leadership still sits in North America, but faster growth in Asia-Pacific and the Middle East and Africa points to widening access and stronger medical-device demand outside mature markets. - The report's company updates suggest competition is centered on device innovation, acquisitions and partnerships rather than one dominant platform.

What's next: - The report expects continued investment in next-generation minimally invasive techniques, liquid embolics, AI-driven diagnostics and personalized medicine. - Telemedicine and cross-border neurovascular care corridors are also positioned as future growth areas. - Market leadership is likely to favor companies that can pair procedural safety with faster recovery and more tailored AVM treatment plans.